Drug Trial Radar · NCT00049998
Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Mar 4, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
760
Actual
Start
Oct 2001
Primary completion
Apr 2004
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Nov 20, 2002
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to collect information on how effective and how well tolerated an oral investigational drug is compared to a standard intravenous drug in patients with pretreated, advanced non-small lung cancer (NSCLC).
Conditions
- Non-Small-Cell Lung Cancer
Interventions
topotecanDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- One-year survival rate
Locations
114 sites in 31 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Adelaide, South Australia, Australia
GSK Investigational Site
Bedford Park, South Australia, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Ringwood East, Victoria, Australia
GSK Investigational Site
Innsbruck, Austria
GSK Investigational Site
Sankt Pölten, Austria
GSK Investigational Site
Vienna, Austria
GSK Investigational Site
Braasschaat, Belgium
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Edegem, Belgium
GSK Investigational Site
Liège, Belgium
GSK Investigational Site
Sydney, Nova Scotia, Canada
GSK Investigational Site
Oshawa, Ontario, Canada
GSK Investigational Site
Thunder Bay, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Greenfield Park, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Sainte-Foy, Quebec, Canada
GSK Investigational Site
Beijing, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Shanghai, China
GSK Investigational Site
Tianjin, China
GSK Investigational Site
Wangfujing, Beijing, China
GSK Investigational Site
Xi'an, Shaanxi, China
GSK Investigational Site
České Budějovice, Czechia
GSK Investigational Site
Kladno, Czechia
GSK Investigational Site
Prague, Czechia
GSK Investigational Site
Herlev, Denmark
GSK Investigational Site
Odense C, Denmark
GSK Investigational Site
Helsinki, Finland
GSK Investigational Site
Turku, Finland
GSK Investigational Site
Caen, France
GSK Investigational Site
Dijon, France
GSK Investigational Site
Strasbourg, France
GSK Investigational Site
Toulon Naval, France
GSK Investigational Site
Vesoul, France
GSK Investigational Site
Gauting, Bavaria, Germany
GSK Investigational Site
Munich, Bavaria, Germany
GSK Investigational Site
Regensburg, Bavaria, Germany
Showing 40 of 114 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.